KPTI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Karyopharm Therapeutics Inc (KPTI) is not a strong buy for a beginner investor with a long-term focus at this time. While there are some positive indicators, such as bullish moving averages and a recent Overweight rating from an analyst, the significant insider selling, lack of recent news catalysts, and ongoing financial losses make it prudent to hold off on investing for now.
The technical indicators show a mixed picture. The MACD is positive but contracting, RSI is neutral at 55.303, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are Pivot: 9.072, R1: 10.703, S1: 7.441, R2: 11.711, S2: 6.433. However, the stock recently dropped 7.33% in regular trading, with a slight recovery of 1.71% post-market.
Bullish moving averages.
Overweight rating from Cantor Fitzgerald with a 70% probability of success in the Phase 3 SENTRY trial for myelofibrosis.
Revenue increased by 11.58% YoY in Q4 2025.
Insiders are selling heavily, with a 599.43% increase in selling over the past month.
The company is still unprofitable, with a net income of -$102.2M in Q4
No recent news or major catalysts to drive the stock higher.
High implied volatility (362.58), indicating uncertainty.
In Q4 2025, revenue increased by 11.58% YoY to $34.08M. However, the company remains unprofitable, with a net income of -$102.2M (up 232.03% YoY) and an EPS of -5.68 (improved by 54.77% YoY). Gross margin is strong at 95.65%, up slightly by 0.01% YoY.
Cantor Fitzgerald initiated coverage with an Overweight rating, citing a 70% probability of success in the Phase 3 SENTRY trial for myelofibrosis. A successful trial could significantly reposition the company, offering upside potential.
